Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15144439 | 0.98 | POLB (0.36) | POLBTSHRSMN1; SMN2 | |
| SCHEMBL15135657 | 0.98 | POLB (0.36) | POLBTSHRSMN1; SMN2 | |
| SCHEMBL8693325 | 0.95 | POLB (0.37) | POLBTSHRSMN1; SMN2 | |
| SCHEMBL8693335 | 0.95 | POLB (0.37) | POLBTSHRSMN1; SMN2 | |
| SCHEMBL8476517 | 0.90 | PAOX (0.38) | POLBTSHRSMN1; SMN2 | |
| SCHEMBL8476513 | 0.90 | PAOX (0.38) | POLBTSHRSMN1; SMN2 | |
| SCHEMBL26537222 | 0.89 | POLB (0.34) | POLBTSHR | |
| SCHEMBL8476699 | 0.88 | PAOX (0.41) | POLBTSHRSMN1; SMN2 | |
| SCHEMBL8476697 | 0.88 | PAOX (0.41) | POLBTSHRSMN1; SMN2 | |
| SCHEMBL8362134 | 0.87 | POLB (0.33) | POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129065-B1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | AKAMARA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20250340519-A1 | RADIOLABELLED COMPOUND | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2025-11-06 | — | — | US | disclosed |
| EP-4624459-A2 | RADIOLABELLED COMPOUND | Oxford University Innovation Limited (GB) | 2025-10-01 | — | — | EP | disclosed |
| CN-118955971-A | Composite film material capable of enhancing toughness of cycloolefin copolymer film and preparation method thereof | 无锡阿科力科技股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023165987-A1 | PRECURSOR MARKERS AND RADIOTRACERS WITH THREE OR MORE TARGETING VECTORS FOR THERANOSTICS USED IN NUCLEAR MEDICINE | Atoms for Cure GmbH (DE) | 2023-09-07 | — | — | WO | disclosed |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | Akamara Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2023118195-A1 | FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS | Atoms for Cure GmbH (DE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022258637-A1 | TRISLINKER-CONJUGATED DIMERIC LABELLING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM | Atoms for Cure GmbH (DE) | 2022-12-15 | — | — | WO | disclosed |
| US-11325942-B2 | Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis | BEIJING ARTIVILA BIOPHARMA CO. LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| EP-1860158-B1 | Particles comprising a substrate and an anion-binding layer | MERCK PATENT GMBH (DE) | 2013-12-04 | — | — | EP | disclosed |
| US-7914893-B2 | Particles comprising an anion-binding layer containing anion-forming organic active compounds, and method of making and using thereof | MERCK PATENT GMBH (DE) | 2011-03-29 | — | — | US | disclosed |
| US-20070275244-A1 | Particles | MERCK PATENT GMBH | 2007-11-29 | — | — | US | disclosed |
| EP-1860158-A2 | Particles comprising a substrate and an anion-binding layer | MERCK PATENT GmbH (DE) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340519-A1 | RADIOLABELLED COMPOUND | PARP3, PARP2, PARP1 | POLB 49/4885TSHR 1271/4885SMN1; SMN2 4502/4885 |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | ABCG2, FCGR2A, ABCB1 | POLB 3973/4885TSHR 2328/4885SMN1; SMN2 3007/4885 |
| US-11325942-B2 | Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis | TBCA, BCL3, BCL6 | POLB 3115/4885TSHR 4093/4885SMN1; SMN2 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.